Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Hutchmed China's Sovleplenib?
Sovleplenib is a small molecule commercialized by Hutchmed China, with a leading Phase I program in Idiopathic Thrombocytopenic Purpura (Immune...
Sovleplenib by Hutchison MediPharma for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Sovleplenib is under clinical development by Hutchison MediPharma and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
Sovleplenib by Hutchison MediPharma for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
Sovleplenib is under clinical development by Hutchison MediPharma and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....